Business Segments — Selling, general, and administrative
Neurocrine Biosciences Business Segments — Selling, general, and administrative increased by 5.5% to $318.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.2%, from $276.50M to $318.50M. Over 3 years (FY 2022 to FY 2025), Business Segments — Selling, general, and administrative shows an upward trend with a 15.4% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
A lower ratio of SG&A to revenue indicates improved operational efficiency and scalability.
Detailed definition
Encompasses the overhead costs of running the business, including sales force expenses, marketing, legal, and corporate...
Peer comparison
Standard operating expense metric; peers are compared based on their ability to scale revenue faster than SG&A.
nbix_segment_reportable_segment_selling_general_and_administrativeHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $188.18M | $188.18M | $188.18M | $188.18M | $221.90M | $221.90M | $221.90M | $221.90M | $243.10M | $242.00M | $234.30M | $287.80M | $276.50M | $286.30M | $291.60M | $301.80M | $318.50M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +17.9% | +0.0% | +0.0% | +0.0% | +9.6% | -0.5% | -3.2% | +22.8% | -3.9% | +3.5% | +1.9% | +3.5% | +5.5% |
| YoY Change | — | — | — | — | +17.9% | +17.9% | +17.9% | +17.9% | +9.6% | +9.1% | +5.6% | +29.7% | +13.7% | +18.3% | +24.5% | +4.9% | +15.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's business segments — selling, general, and administrative?
- Neurocrine Biosciences (NBIX) reported business segments — selling, general, and administrative of $318.50M in Q1 2026.
- How has Neurocrine Biosciences's business segments — selling, general, and administrative changed year-over-year?
- Neurocrine Biosciences's business segments — selling, general, and administrative increased by 15.2% year-over-year, from $276.50M to $318.50M.
- What is the long-term trend for Neurocrine Biosciences's business segments — selling, general, and administrative?
- Over 3 years (2022 to 2025), Neurocrine Biosciences's business segments — selling, general, and administrative has grown at a 15.4% compound annual growth rate (CAGR), from $752.70M to $1.16B.
- What does business segments — selling, general, and administrative mean?
- The overhead costs required to operate the business and market its products.